SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present seven abstracts focused on the company’s growing capabilities for discovering and advancing genetic medicines for heart disease at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held May 7-11, 2024, in Baltimore, MD.

加利福尼亚州南旧金山，2024年5月2日（环球通讯社）--Tenaya Therapeutics，Inc.（纳斯达克：TNYA），一家临床阶段的生物技术公司，其使命是发现、开发和提供潜在的治疗方法，以解决心脏病的根本原因，今天宣布将在即将于2024年5月7日至11日在马里兰州巴尔的摩举行的美国基因与细胞治疗学会（ASGCT）第27届年会上发表七篇摘要，重点介绍该公司在发现和推进心脏病遗传药物方面不断增长的能力。

Tenaya has established integrated internal capabilities to broadly enable modality agnostic target validation and the design and manufacture of adeno associated virus (AAV)-based genetic medicines focused on the treatment of heart diseases. The company’s pipeline includes two clinical-stage gene therapies for cardiomyopathies, as well as earlier-stage research related to gene therapy, gene editing and cardiac cell regeneration, all using adeno-associated virus (AAV) as a delivery vehicle.

Tenaya已经建立了综合的内部能力，可以广泛地进行不可知模式的目标验证，并设计和制造基于腺相关病毒（AAV）的基因药物，重点治疗心脏病。该公司的产品线包括两种针对心肌病的临床阶段基因疗法，以及与基因疗法，基因编辑和心脏细胞再生相关的早期研究，所有这些都使用腺相关病毒（AAV）作为递送载体。

Tenaya’s seven presentations at this year’s ASGCT will highlight new capsid engineering insights, the company’s emerging gene editing efforts, and manufacturing process optimizations intended to enhance the safety and efficacy profiles of AAV-based gene therapies. Details of the presentations are as follows: Capsid Engineering and PromotersTenaya has established an active capsid engineering effort encompassing the identification and comparison of known and novel capsids, which are then tested across multiple species to characterize transduction and expression in specific heart cells and/or liver detargeting.

Tenaya在今年的ASGCT上的七次演讲将重点介绍新的衣壳工程见解，该公司新兴的基因编辑工作以及旨在提高基于AAV的基因疗法的安全性和有效性的制造过程优化。介绍的细节如下：衣壳工程和PromotersTenaya已经建立了一个积极的衣壳工程工作，包括鉴定和比较已知和新型衣壳，然后在多个物种中进行测试，以表征特定心脏细胞和/或肝脏中的转导和表达。去靶向。

At ASGCT, new data from murine and non-human primate studies will be presented comparing previously identified AAV-b.

在ASGCT，将提供来自鼠类和非人灵长类动物研究的新数据，比较先前鉴定的AAV-b。